Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical
resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of
adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the
time of resection.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania